About Us
About Us
Govindarajan Narayanan, M.D. (Founder of SpectrumCancer.com)
Dr. Govindarajan Narayanan is an interventional radiologist at two of Baptist Health South Florida’s service lines: Miami Cardiac and Vascular Institute, and Miami Cancer Institute, where he has been named chief of interventional oncology. He is Board-certified in diagnostic radiology and holds a certificate of added qualification in interventional radiology. Dr. Narayanan has a medical degree from Madras Medical College in India and has had residency training in nuclear medicine at Methodist Hospital of Brooklyn and Memorial Sloan Kettering Cancer Center in New York, as well as a residency in diagnostic radiology at St. Barnabas Medical Center in New Jersey. His fellowship years encompassed training in interventional radiology at the Medical University of South Carolina and Stony Brook University Hospital in New York. Most recently, he served as medical director of Interventional Radiology at University of Miami Hospital and Clinics, and as the founding chairman of the Department of Interventional Radiology at the University Of Miami Miller School Of Medicine, where he also served as a professor of interventional radiology and of urology. Dr. Narayanan’s primary clinical research interests include pancreatic, liver and colon cancer. He is widely published in such high-impact medical journals as Cancer, Journal of Vascular and Interventional Radiology and Cardiovascular and Interventional Radiology and serves as a reviewer and editor for several scientific publications. He has authored text book chapters and is an invited faculty member and speaker at national and international scientific meetings.
Scientific Advisory Board
Meet Spectrum Cancer’s Medical Advisory Board. Composed of esteemed healthcare professionals and experts, they provide strategic guidance and insights to ensure the highest standards of medical information and patient care. With diverse expertise spanning various disciplines, the board plays a crucial role in advising on clinical protocols, medical research, and fostering innovation in healthcare delivery. Their collective wisdom and dedication support our commitment to providing the most relevant and accurate information in cancer care.
Riccardo Lencioni, M.D., FSIR, FCIRSE, EBIR
Riccardo Lencioni is Professor of Radiology at the University of Pisa School of Medicine in Pisa, Italy, and the Director of the Cancer Imaging Program at the Department of Radiology and Nuclear Medicine of Pisa University Hospital. He is also the Vice President for Medical Education at the University of Pisa and an Honorary Research Professor of Interventional Oncology at the Miami Cancer Institute in Miami, USA. Riccardo Lencioni is known especially for his highly influential research work in liver cancer. He has been a leading member of several expert panels developing recommendations for research and clinical management of hepatocellular carcinoma. He is also known for having established modified RECIST criteria for the assessment of tumor response in hepatocellular carcinoma. Riccardo Lencioni has been the Founding Chairman of the European Conference of Interventional Oncology, a co-Founder and Chairman of the World Conference of Interventional Oncology, and a Founding Governing Board Member and Executive Secretary of the International Liver Cancer Association. He is currently the Co-Director of the SPECTRUM Interventional Oncology Multidisciplinary Conference. Professor Lencioni has published over 230 articles in peer-reviewed international journals indexed in PubMed and numerous chapters in textbooks of interventional radiology, gastroenterology, oncology and surgery. In addition, he has been the editor of 12 books. According to SCOPUS, citations of his publications currently exceed 37,000, for an h-index of 77.
Martijn R. Meijerink, M.D., Ph.D.
Interventional radiologist with interventional oncology as special field of expertise. Head fellowship and differentiation program interventional radiology for (resident) radiologists. Certified senior investigator interventional radiology and oncology trial reader. Primary investigator of several multicenter controlled studies in the field of thermal and non-thermal ablation and trans-arterial therapies for malignancies within the liver, pancreas and biliary tract. Expert in open and percutaneous minimally invasive image guided treatments such as radiofrequency ablation, microwave ablation, irreversible electroporation (nanoknife), transarterial bland embolization, chemo- and Y90 radioembolization. General expertise in treatment of vascular interventions such as acute traumatic and non-traumatic hemorrhages, peripheral arterial disease (PTA and stenting), venous interventions and non-vascular interventions such as percutaneous transhepatic cholangiography, abscess drainage, ultrasound and CT guided biopsy and percutaneous nephro.
Peter Hosein, M.D.
Dr. Hosein sees patients with cancers of the esophagus, stomach, liver, bile ducts, pancreas, small bowel, colon, rectum and anal canal, as well and gastrointestinal neuroendocrine cancers. He works closely with surgical oncologists, colorectal surgeons, radiation oncologists and interventional radiologists at Sylvester to coordinate multidisciplinary care for patients with gastrointestinal cancers; He is also a part of the HIPEC (Hyperthermic Intraperitoneal Chemotherapy) team for patients with peritoneal malignancies.
Reshma L. Mahtani, D.O.
Dr. Reshma Mahtani serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer. Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals. She has served on the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She is the Editor-in-Chief of Practice Updates (an online medical education platform for physicians). She is on the Board of Directors for LBBC (Living Beyond Breast Cancer). She has a passion for medical education and founded a medical education initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. Finally, she is involved in several initiatives that enhance patients’ access to healthcare and community collaborations for education and advocacy.
Caio Max S. Rocha Lima, M.D.
Caio Max S. Rocha Lima, M.D. is the M. Robert Cooper Professor in Medical Oncology. He is the Co-leader GI Oncology and Co-leader Phase I Programs at the Division of Hematology and Oncology at Wake Forest School of Medicine in Winston-Salem, NC. Prior to join Wake Forest School of Medicine, Dr. Rocha Lima was the Associate Cancer Center Director for Translational Research Gibbs Cancer Center & Research Institute and CMO Guardian Research Network Dr. Rocha Lima received his medical degree from the Federal University of Bahia-Salvador and later pursued residency training at the Clinical Hospital of Sao Paulo University; both in his native country of Brazil.
Afterwards Dr. Rocha Lima completed a fellowship in hematology/oncology at the Medical University of South Carolina. Dr. Rocha Lima was an assistant Professor of Medicine at Moffitt Cancer Center in Tampa, Fl. As a full Professor, at the University of Miami, he was the Program Co-Leader for Pancreatic/Hepatobiliary and Colorectal Cancer Site Disease Groups. He also co-lead the Phase I program at the University of Miami.
Dr. Rocha Lima’s professional memberships include the American Society of Hematology, The American Society of Clinical Oncology, the East Cooperative Oncology Group, and the European Society of Medical Oncology, where he served as the USAASCO representative in 2002-2003. Dr. Rocha Lima has engaged in a considerable number of studies that investigate the use of novel agents to treat solid tumors, including pancreatic cancer, lung cancer, and colorectal cancers. He was frequently involved as a principal or co-investigator in many clinical trials including the PI of a phase III trial that involved the Americas, Asia and Australia in Pancreas cancer. Dr. Rocha Lima’s research has been widely published in journals such as Journal of Clinical Oncology, Chest, Oncology, Seminars in Oncology, Cancer, and The Annals of Oncology.
Yilun Koethe, M.D.
Dr. Koethe is an interventional radiologist at TRG Imaging in Portland, OR. She is also proud to have been the former Director of Interventional Oncology and Assistant Professor at Oregon Health & Science University. She is the vice chair of the Early Career Section of the Society of Interventional Radiology and is a member and volunteer at the Society of Interventional Oncology and at the American Board of Radiology. She specializes in interventional oncology and musculoskeletal interventions.
Flavio Rocha, M.D., FACS, FSSO
Dr. Rocha is the Hugh and Georgeina Hedinger Chair of Surgical Oncology at Oregon Health and Science University (OHSU) in Portland, OR. He also serves as the Physician-in-Chief of the Knight Cancer Institute at OHSU. He graduated with honors from the University of Chicago Pritzker School of Medicine. After training in general surgery at the Brigham and Women’s Hospital and Harvard Medical School both in Boston, he completed both a surgical oncology and hepatopancreatobiliary surgery fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Rocha’s clinical practice encompasses all aspects of benign and malignant disease of the liver, bile ducts and pancreas. He has been funded by the AAS, NIH/NIDDK, ASCO and the Cholangiocarcinoma Foundation.
Dr. Rocha currently sits on the editorial boards of Surgery, HPB, Annals of Surgical Oncology, and Journal of Surgical Oncology. He has served on the NCI Pancreas Task Force, ASCO Gastrointestinal Cancers Advisory Council and ASTRO Liver Cancer Guidelines Committee. He is currently the surgical lead of the International Cholangiocarcinoma Research Network (ICRN), Vice-Chair of the Southwest Oncology Group (SWOG) Surgery Committee, GI Surgery Working Group Chair at Eastern Cooperative Group (ECOG-ACRIN) and Secretary/Treasurer of the North Pacific Surgical Association.
Bradford Wood, M.D.
Dr. Bradford Wood is Chief of IR and directs a multi-disciplinary team (NIH Center for Interventional Oncology) that develops and translates devices, software, and navigation approaches for cancer patients via novel local and regional minimally invasive, image- guided therapies. He holds several patents, authored books on radiology and interventional urology, and co-authored more than 600 publications (H-index of 100) including JAMA, NEJM, Nature Communications, Science, Lancet, Blood, Chest, Cancer, JCO, CCR, JAMA Oncology, Hepatology, Medical Physics, and Scientific Reports. Dr. Wood and his team have mentored hundreds of students, fellows, physicians, nurses, and scientists and continue to drive innovation in Interventional Oncology.
Advisory Board
Meet Spectrum Cancer’s Advisory Board. A dynamic collective of seasoned professionals dedicated providing invaluable insights, strategic guidance, and thought leadership. Our board is comprised of industry leaders, strategic thinkers, and visionary experts who bring a wealth of experience and diverse perspectives to Spectrum Cancer.
Yekaterina Chudnovsky
Yekaterina “Katie” Chudnovsky is an attorney, venture investor, dedicated patient advocate, and supporter of medical research. She firmly believes in the power of scientific inquiry to unearth groundbreaking treatments for cancer patients. She is deeply committed to the cause, leading and participating in countless research projects that aim to expand our understanding of rare cancers and the most effective ways to fight them.
Katie’s philanthropic endeavors have significantly advanced the reach and resources of cancer research. Her efforts have provided financial support for hundreds of patients in need and understands that without sufficient funding, even the most promising research projects remain unrealized. Katie serves as the chairperson of GI Research Foundation (GIRF) for the University of Chicago Digestive Diseases Center and has previously served as their President and Board Member for 12 years. Additionally, Katie currently serves on the Board of Directors for Elicio Therapeutics, Immix Biopharma, XCures, Colorectal Cancer Alliance (CCA) and is a Board Observer for MiNK Therapeutics.
Katie holds a BA from Northwestern University and a JD from DePaul University.
Richard Stark
Richard Stark is a senior-level executive with more than 25 years of US and international leadership success in startup, turnaround, and growth environments. He has a documented history of successfully building and executing commercial strategies, developing and managing high-performance teams, and running successful businesses.
Mr. Stark is currently the CEO of Innoblative Designs, Inc., an early-stage electrosurgical medical device company developing advanced radiofrequency ablation (RFA) technology for breast cancer therapy and beyond. He also serves as a Business Development Advisor at Immunophotonics, pioneering the burgeoning field of Interventional Immuno-Oncology™ through the development of novel treatments for solid-tumor cancers. Additionally, he is a Business Advisor at BetaGlue Therapeutics, pioneering highly innovative precision radiotherapy products, and a Senior Advisor at Polyembo, developing a revolutionary coil technology to obstruct or reduce the rate of blood flow in the peripheral vasculature. Mr. Stark is also a Business Advisor with Pleural Dynamics, an early-stage medical device startup developing best-in-class solutions for the management of chronic, recurrent fluid collections within the body, such as recurrent pleural effusions and refractory ascites for cancer patients.
Mr. Stark also served on the Board of Directors of Embomedics, Inc., developer of a natural resorbable gel product used to deliver therapeutic drugs into the body for various treatments, including pain.
Linda Corey
Linda was born in Wyoming and grew up in the scenic landscapes of West Virginia before making Miami her beloved home for over three decades. Her passion for community service and philanthropy has left an indelible mark on South Florida. Throughout her years in Miami, Linda has been a dedicated supporter of numerous charitable organizations, including the Chapman Partnership for the Homeless, Lighthouse for the Blind, Kristi House, The Villagers and the Junior League. Linda’s contributions extend beyond mere financial support; she actively engages as a member of the Citizens Board at the University of Miami and assists with shaping the university’s outreach and community initiatives. Linda and her husband Phil’s impact on healthcare in Miami is profound, having been contributors to the University of Miami Medical School and playing a pivotal role in the establishment of the Miami Transplant Institute. Phil and Linda’s philanthropic efforts have not only enhanced medical care in the region but have also supported groundbreaking research and patient care.